Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity now available at the Rutherford Cancer Centre North West in Liverpool.
Dr Muthiah Sivaramalingam has been a consultant in Clinical Oncology since 2007 and has been Principal Investigator for many clinical trials in Oncology. Dr Muthiah Sivaramalingam holds full-time NHS roles and undertakes private consultations for patients with private health insurance, self-paying patients and patients that seek second opinions.
Royal College of Radiologists
Dr Muthiah Sivaramalingam's research interests include IMRT, Immunotherapy and Modern Radiotherapeutic techniques and innovations.
Dr Muthiah Sivaramalingam does not hold a share or financial interest in the Rutherford Cancer Centres or another Rutherford Health plc company.
Dr Muthiah Sivaramalingam does not have a share or financial interest in equipment used at the Rutherford Cancer Centres or another Rutherford Health plc company.
Dr Muthiah Sivaramalingam does not hold any paid advisory role(s) at the Rutherford Cancer Centres or on behalf of Rutherford Cancer Centres or Rutherford Health plc.